ABSTRACT Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disorder of
unknown cause with a highly variable and unpredictable clinical course. The advances …

Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis
is complex and encompasses multiple molecular pathways. The first-generation antifibrotics …

Background: Idiopathic pulmonary fibrosis (IPF) is the most common fibrosing lung disease
and is caused by excessive lung scarring. IPF-associated severe mortality can be attributed …

Introduction Idiopathic pulmonary fibrosis (IPF) is an age-related disease of unknown cause.
The disease is characterized by relentless scarring of the lung parenchyma resulting in …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …

Introduction: Idiopathic pulmonary fibrosis is a chronic, progressive fibrotic lung disease of
unknown etiology associated with a high morbidity and mortality. The hallmark of the …

Idiopathic pulmonary fibrosis (IPF) is an aging-associated, recalcitrant lung disease with
historically limited therapeutic options. The recent approval of two drugs, pirfenidone and …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal interstitial lung
disease. After many drugs failed in clinical trials, improvements in the understanding of the …